Keros Therapeutics, Inc.

NasdaqGM KROS

Keros Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -27.50%

Keros Therapeutics, Inc. Gross Profit Margin is -27.50% for the Trailing 12 Months (TTM) ending September 30, 2024, a 99.90% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Keros Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -27,812.50%, a -30,105.43% change year over year.
Keros Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 92.69%, a 100.46% change year over year.
Keros Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -19,959.00%, a -10,797.03% change year over year.
Keros Therapeutics, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -183.16%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGM: KROS

Keros Therapeutics, Inc.

CEO	Dr. Jasbir S. Seehra Ph.D.
IPO Date	April 8, 2020
Location	United States
Headquarters	99 Hayden Avenue
Employees	160
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Key trends

Past 5 years